A Study to Evaluate the Safety, Tolerability and Plasma Concentration Profiles of MK0633 in Asthmatic Children Aged 12 to Less Than 16 Years (0633-019)

Phase 1 Completed 12 enrolled Merck Sharp & Dohme LLC

RandomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the safety, tolerability and pharmacokinetics (PK) of MK0633 in adolescent mild-to-moderate asthma patients to permit further clinical investigation.

Timeline

Start: 2008-05
Primary completion: 2008-07
Completion: 2008-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SETILEUTON	Small molecule	50 mg	Oral

A Study to Evaluate the Safety, Tolerability and Plasma Concentration Profiles of MK0633 in Asthmatic Children Aged 12 to Less Than 16 Years (0633-019)

Summary

Timeline

Drugs

Indications